Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celecoxib + esomeprazole is a combination of two pharmaceutical agents used together, typically in patients at high risk for gastrointestinal complications who require anti-inflammatory therapy. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor classified as a nonsteroidal anti-inflammatory drug (NSAID), which reduces inflammation and pain by selectively inhibiting the COX-2 enzyme involved in prostaglandin synthesis. Esomeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. The combination aims to provide effective pain and inflammation relief while reducing the risk of NSAID-induced gastrointestinal ulcers or bleeding, especially in patients with arthritis or those requiring long-term NSAID therapy[1]. Clinical studies have shown that combining celecoxib with esomeprazole can be more effective than celecoxib alone for preventing recurrent ulcer bleeding[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on celecoxib + esomeprazole.